Schedule 13D ownership disclosure

Entrada Therapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 29384C108

Event date: 2025-11-14

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • 5AM Ventures V, L.P.Reported CIK 0001674324

    Shares: 2,963,066.00 · Class: 7.8%

  • 5AM Partners V, LLCReported CIK 0001791889

    Shares: 2,963,066.00 · Class: 7.8%

  • 5AM Opportunities I, L.P.Reported CIK 0001753000

    Shares: 1,093,313.00 · Class: 2.9%

  • 5AM Opportunities I (GP), LLCReported CIK 0001790778

    Shares: 0.00 · Class: 2.9%

  • Andrew J. SchwabReported CIK 0001598549

    Shares: 4,056,379.00 · Class: 10.6%

  • Kush ParmarReported CIK 0001664281

    Shares: 4,123,849.00 · Class: 10.8%

  • Scott M. RocklageReported CIK 0001219014

    Shares: 2,963,066.00 · Class: 7.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001674324-25-000005
Form type
SCHEDULE 13D/A
Filer
5AM Ventures V, L.P.
CIK
CIK 1674324
Filed
Nov 18, 2025
Reporting period
Nov 14, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub